Hep Summer 2016 - Special Issue

Hep Summer 2016 - Special Issue

In every issue of HEP, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.

Also Available On:



Super Friend: Gloria Guzman Inspires Others Hoping for a Hep C Cure

As a peer educator, Gloria Guzman inspires others hoping for a hepatitis C cure.

From the Editor

An illustraion of a globe

What a Wonderful World

Regardless of the hurdles many HCV-positive people face, there is a better chance to get cured than ever before.


A smiling Caucasian couple

Youthful Drug Use Not to Blame?

Another explanation for hep C among baby boomers

Test Tubes with red liquid

Screening Among Baby Boomers Is Inadequate

People on Medicaid are less likely to be treated.

An button with Oklahoma

Cherokee Nation Seeks Complete Elimination of Hep C

They are the first community in the United States to set this goal

A maginfying glass looking at the words "Health Insurance Policy"

Hep C Health Insurance Discrimination

An analysis from Harvard University

U.S. Addiction Treatment Is Hard to Get

More difficult than getting drugs that cause addiction

Treatment News

An illustration of a liver and virus particles

Hepatitis B and C Drive Liver Cancer Rates

Liver cancer incidence is steadily rising in the United States, driven by hepatitis B and C virus infection in an aging population.

Traffic light with green light illuminated

Expanded Approval for Daklinza/Sovaldi

The FDA expanded the approved uses of the combination hep C virus regimen of Bristol-Myers Squibb’s Daklinza and Gilead Sciences’ Sovaldi.

A hand holding up a calculator

Treating Hepatitis C Earlier Is More Cost Effective

Using Gilead Sciences’ Harvoni to treat hep C in certain people is more cost effective than waiting until their liver disease progresses.

A stethoscope on a red plastic heart

Hep C and Heart Disease Link

People with hep C virus (HCV) have higher rates of cardiovascular disease (CVD) than HCV-negative individuals with similar risk factors.

A red and white seal of "Approval"

FDA OKs Merck’s Zepatier

The FDA has approved Merck’s once-daily, fixed-dose combination tablet Zepatier to treat people with genotypes 1 and 4 of hep C.


Hot topics